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Pre-eclampsia, an obstetric disorder specific to human pregnancy remains a major cause of maternal 
mortality and morbidity globally. The acute phase proteins, C-reactive protein (CRP) and serum amyloid 
A (SAA) and other known markers of inflammation have been implicated in the development of pre-
eclampsia. However, a dose-response relationship between PE and inflammation remains to be elucidated. 
This study aims to assess CRP and SAA levels in HIV-associated pre-eclamptic pregnancies.  
 
Method:  
The study population (n = 76) was divided based on pregnancy type ie., normotensive (n = 38) and pre-
eclamptic (n = 38) and further stratified by HIV status. CRP and SAA levels were quantified using a Bioplex 
immunoassay.  
 
Results:   
CRP was significantly decreased in pre-eclamptic compared to normotensive pregnancies, irrespective of 
HIV status (p = 0.0073).  Based on HIV status, there was an upregulation of CRP levels albeit non-
significantly, regardless of pregnancy type (p = 0.74). In contrast, SAA did not differ by pregnancy type, 
HIV status and across all study groups respectively (p = 0.07; p = 0.44; p = 0.76). However, a slight 
increase of SAA levels albeit non-significantly was noted in pre-eclamptic versus normotensive pregnancy. 
Furthermore, although serum SAA levels did not differ based on HIV status and across all study groups, an 
increasing trend was noted with regards to HIV status ie., in HIV- positive vs HIV -negative and PE-positive 





This study demonstrates significant reduction of CRP and with a concomitant non-significant elevation of 
SAA in PE versus healthy pregnant women. Decreased CRP is suggestive of a neutralized immune response 




























































1.1 Maternal Mortality: A Global Crisis 
Over the years maternal mortality rates have decreased, however, this still remains a major global concern. 
Every day women die from pregnancy related complications and during childbirth. The global estimate of 
women dying from complications arising during and after child birth and pregnancy is approximately 
303 000 deaths (WHO, 2015). While most of them can be prevented, approximately 99% of all maternal 
deaths occur in developing countries (WHO, 2015). In developing countries, it is estimated that a woman 
faces a risk of about 33 times greater of dying from pregnancy-related complications in her lifetime, in 
comparison to another woman residing in a developed country (WHO, 2015). More than half of all maternal 
deaths occur in Sub-Saharan Africa, with about 546 maternal deaths per 100 000 live births per year (WHO, 
2015). Of this, 138 deaths per 100 000 live births occur in South Africa which is a middle-low income 
country (WHO, 2015). 
Obstetric haemorrhage is the major cause of maternal mortality contributing 27 % of all maternal deaths 
worldwide, whilst in South Africa it accounts for 16%, followed by hypertensive disorders (14%).  Non-
pregnancy related infections account for 34.7 % of all maternal deaths (Mothers, 2014).  
 
1.2 Human Immunodeficiency Virus Infection (HIV): A Global Pandemic 
The HIV epidemic remains a major health concern globally and continues to grow. In the year 2015, there 
was a global estimate of 2.1 million new HIV infections resulting to a total of 36.7 million people living 
with HIV (UNAIDS, 2016). Additionally, 1.1 million deaths occurred due to HIV-related illness in the 
same year (UNAIDS, 2016). Sub-Saharan Africa is dubbed as the epicenter of this global epidemic with 
approximately 7 million people living with HIV in South Africa alone (UNAIDS, 2016).  
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1.2.1 HIV and Women 
HIV and pregnancy-related illnesses are the leading cause of maternal deaths worldwide. This remains a 
serious obstetric dilemma as it has devastating consequences on women of reproductive age (Mothers, 
2014).Young women face a threefold risk of HIV infection and specifically in South Africa; the prevalence 
of HIV infection is greater in young women aged 15-24 years compared to their male counterparts 
(UNAIDS, 2016). 
 In South Africa, non-pregnancy related illnesses (mostly being HIV) account for 35.8% of all maternal 
deaths as well as a HIV prevalence rate of 37.7% in pregnant women in the KwaZulu-Natal province. 
Furthermore, women of reproductive age contribute a HIV incident rate of 18.8% in the same province 
(Saving Mothers Report, 2014, Department of Health SA, 2012). 
 
1.3 Hypertension 
Hypertensive disorders along with haemorrhage and infection are the cause of the majority of all maternal 
deaths and morbidity. Specifically, women younger than 20 years of age face a greater risk of death as a 
result of hypertension during pregnancy. In South Africa, 14.8% of maternal deaths is attributed to 
hypertension during pregnancy, with 83% these pregnancies complicated by pre-eclampsia (PE) 
(Thakoordeen, 2017). KwaZulu-Natal has a PE prevalence rate of 12% which makes this province an ideal 




Pre-eclampsia is a common disorder specific to human pregnancy which clinically presents with an elevated 
blood pressure (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) and 
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proteinuria (≥ 300 mg per 24 hours) after 20 weeks of gestation or during labour and/or postpartum 
(Gathiram and Moodley, 2016, Kalumba et al., 2013) 
Additionally, PE presents with many other clinical manifestations and serum markers for haemolysis, 
coagulation, oedema, liver and renal organ impairment (Engin-Üstün et al., 2007, Gathiram and Moodley, 
2016). Furthermore, if untreated, this multi-systemic syndrome can progress to eclampsia with presentation 
of severe symptoms including seizures and or cortical blindness following an asymptomatic period 
(Håpnes, 2014). This particularly poses a major threat to both the mother and baby as it may result in 
maternal and perinatal death (Håpnes, 2014). 
Pre-eclampsia is characterized into two types namely; early onset pre-eclampsia (EOPE) and late onset pre-
eclampsia (LOPE) in which clinical manifestation occurs at 33 weeks and both at and after 34 weeks’ 
gestation respectively (Raymond and Peterson, 2011). Most of the pre-eclamptic patients are diagnosed 
with LOPE; however, the high maternal and neonatal mortality and morbidity rates are attributable to EOPE 
(Gathiram and Moodley, 2016). 
Although the exact cause of PE remains unclear, it is postulated to be caused by an excessive maternal 
inflammatory response to pregnancy which is associated with reduced placental perfusion and an increased 
maternal inflammatory response which leads to widespread endothelial dysfunction (Jeyabalan, 2013, 
Kristensen et al., 2009). The only known cure for this disorder is placental and fetal delivery; however, this 
may not always be the best of options at the time of diagnosis. Administration of treatment to pre-eclamptics 
is greatly dependent on the severity of the disorder and gestational age (Chaiworapongsa et al., 2014a). 
Corticosteroids and anticonvulsants may be administered to mature the foetal lungs and the latter to prevent 
seizures in the event of possible eclampsia. Additionally, treatment may also include medication to lower 




Pre-eclampsia complicates approximately 3-7% of pregnancies globally and is the leading cause of maternal 
and perinatal deaths due to hypertensive disorders (Sansone et al., 2016). The incidence of PE in developing 
countries is about seven times greater than in developed countries (WHO, 2015). The majority of maternal 
deaths are said to be caused by eclampsia rather than pre-eclampsia especially where maternal mortality 
rates are high (Jeyabalan, 2013). Specifically in KwaZulu-Natal, South Africa, the prevalence of PE is 
approximately 12% (Thakoordeen et al., 2017). 
 
2.3 Risk Factors 
The wide spectrum of risk factors associated with PE is largely reflected in the epidemiology of the disease. 
These risk factors are generally grouped into pregnancy-specific and maternal pre-existing characteristics. 
Pregnancy related risk factors include new paternity, primiparity and excessive placental volume. 
Nulliparity has been said to increase the risk of PE by almost three times (Jeyabalan, 2013, Chaiworapongsa 
et al., 2014a).  Maternal characteristics are inclusive of age, race, smoking, obesity, a family history of PE 
and pre-existing conditions such as hypertension, obesity and vascular disorders (Jeyabalan, 2013, 
Chaiworapongsa et al., 2014a, Håpnes, 2014). 
 
3. PATHOGENESIS OF PRE-ECLAMPSIA 
Despite years of research, the exact cause of PE remains obscure. It is however postulated to be part of an 
exaggerated maternal immune response initiated by abnormal placentation. PE is associated with reduced 
placental perfusion possibly as a result of placental hypoxia, inadequate trophoblast invasion and defective 
maternal vascular transformation (Gathiram and Moodley, 2016, Jeyabalan, 2013, Chaiworapongsa et al., 
2014a). This is followed by the release of excess placental debris and various substances including apoptotic 
cells, proinflammatory cytokines, angiogenic [vascular endothelial growth factor (VEGF), placental growth 
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factor (PIGF)] and anti-angiogenic [soluble fms-like tyrosine-1(sFlt-1), soluble endoglin (sEng)] factors 
into the maternal circulation (Kalumba et al., 2013, Gathiram and Moodley, 2016). In normal pregnancy, 
adequate placentation and angiogenesis is achieved through a state of equilibrium between angiogenic and 
anti-angiogenic factors. In PE however, the levels of circulating sFlt-1 are elevated while VEGF and PlGF 
levels are decreased therefore resulting in a shift in the angiogenic-antiangiogenic balance. Consequentially, 
this results in endothelial dysfunction with hypertension and proteinuria, the clinical symptoms of the 
disorder (Levine et al., 2004 and Mbhele et al., 2017) 
 
4   INFLAMMATION AND PRE-ECLAMPSIA 
More recently, an exaggerated maternal inflammatory response has been proposed as one of the causes of 
pre-eclampsia. However, the elucidation of a cause-effect association between the two phenomena has not 
been established (Ramma and Ahmed, 2011). Nonetheless, elevated levels of proinflammatory cytokines 
have been linked with decreased angiogenesis, reduced renal function, elevated blood pressure and 
endothelial dysfunction, all which have been implicated in the pathogenesis of PE (Teran, 2001, Udenze, 
2015). Furthermore, studies using animal models have also shown abnormal expression of cytokines are 
with clinical signs of hypertension, proteinuria and decreased production of nitric acid (Mustafa, 2012, 
Ramma and Ahmed, 2011). 
 
5       INFLAMMATORY MARKERS 
5.1    C-Reactive Protein 
The pentraxin, C-reactive protein (CRP) is a 224 amino acid residue protein with a molecular mass of 
approximately 25k Daltons (Saljoughian, 2008). It is a calcium dependent binding protein with specificity 
for phosphocholine residues on microorganisms (Chandrashekara, 2014). CRP was first described in 1930 
by William Tillet and Thomas Francis (Gruys et al., 2005) through its binding with the C-polysaccharide 
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of a pneumococcus bacterium in the serum of patients with an acute inflammation (Saljoughian, 2008). It 
is a positive acute phase protein and important marker of overall systemic inflammation whose 
concentrations rise dramatically in response to inflammation, infection, tissue injury and trauma 
(Chandrashekara, 2014, Gruys et al., 2005). CRP is expressed mainly in liver hepatocytes in response to 
proinflammatory cytokines, interleukin-6 and tumour necrosis factor-α following stimulation by 
macrophages. Lymphocytes, monocytes, Kupffer cells and neurons can also produce this protein, however, 
in smaller concentrations (Kristensen et al., 2009, Chandrashekara, 2014). CRP binding to pathogens results 
in activation of the complement system thereby promoting opsonisation and clearance of the pathogen 
(Gruys et al., 2005). 
 
5.2 Serum Amyloid A 
Human Serum Amyloid A (SAA) is a member of a multigene family of four genes all located on 
chromosome 11 (Urieli-Shoval, 2000). The four genes encode the isoforms, SAA1 and SAA2 which are 
predominantly synthesized during the acute phase response, SAA3, a pseudogene and SAA4 which is 
constitutively produced in normal tissue and cells such as the large intestine, endothelial cells, spleen etc. 
(Hua et al., 2009, Sun, 2015). SAA differs from its acute-phase homologue CRP, in that it has a half-life of 
one day and diminishes rapidly in serum (Hua et al., 2009). SAA is also a high-density apolipoprotein 
involved in the cholesterol transport system during inflammation. This protein is known to have many 
functions which include adhesion to and migration of monocytes, modulation of neutrophils, upregulation 
of metalloproteinase, production of collagen, chemoattractant function and inhibition of the respiratory 
burst of leukocytes (Gruys et al., 2005, Bargagli et al., 2011, Erdoğan et al., 2012). SAA is also involved 
in the development of systemic Amyloid A amyloidosis (AA amyloidosis), a complication of rheumatoid 
arthritis where it acts as a precursor protein of amyloid AA fibrils (Bargagli et al., 2011). 
Both CRP and SAA correlate with other known markers of inflammation. However, data on the role of 
these acute phase proteins in the pathogenesis of PE is contradictory (Kristensen, 2009, Erdoğan et al., 
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2012). Altered expression of these markers have been demonstrated in pre-eclamptic versus normotensive 
pregnant women (Hubel, 2008, Engin-Üstün et al., 2007, Qiu et al., 2004). In contrast, other studies have 
reported decreases and similarities in pre-eclampsia (Kristensen, 2009, Erdoğan et al., 2012). Moreover, 
the inhibition of nitric oxide synthesis in pregnant rats, due to excessive inflammation, causes proteinuria 
and intensifies endotoxin-induced glomerular thrombosis (Teran, 2001). Similarly, elevated CRP levels 
infused into mice were shown to cause hypertension, proteinuria, glomerular endotheliosis and 
atherosclerosis in the placenta of mice (Mohaupt, 2015). Furthermore, increased SAA levels occur in many 
inflammatory disorders such as atherosclerosis and thrombosis implicating its potential role in endothelial 
dysfunction and in the development of cardiovascular disease (Hua et al., 2009, Sun, 2015). Taken together, 
these findings suggest a potential pathogenic role of CRP and SAA and other markers of inflammation in 
the development of PE. Thus, in the duality of the high maternal deaths due to HIV infection and PE in 














To evaluate the concentration of the acute phase proteins, serum C-reactive protein and serum amyloid A 
in HIV-associated pre-eclamptic pregnancy  
6.1 Specific Objectives  
 
 To determine serum C-reactive protein and serum amyloid A levels in normotensive versus pre-
eclamptic women, irrespective of their HIV status 
 To determine serum C-reactive protein and serum amyloid A levels in HIV-infected versus 
uninfected women, regardless of pregnancy type (normotensive versus pre-eclampsia) 
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differ by HIV status (p = 0.74). In contrast, SAA did not differ by pregnancy type, HIV status and across 
all study groups respectively (p = 0.07; p = 0.44; p = 0.76). Conclusion: This study demonstrates significant 
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In normal pregnancy, a mild maternal inflammatory response enables adequate placentation, fetal tolerance 
and maternal resistance to bacterial and viral infections [1, 2]. In contrast, pre-eclampsia (PE) exhibits an 
excessive maternal immune response which results in a cascade of pathophysiological events and 
subsequent clinical manifestation of the disorder [3, 4]. 
Pre-eclampsia is considered an inflammatory disorder; and several studies suggest a link with intravascular 
inflammation and endothelial dysfunction [5]. Intravascular inflammation is a feature of PE whilst 
endothelial dysfunction is postulated to be a secondary phenomenon [6]. Nevertheless, the elucidation of a 
cause-effect relationship of PE remains unclear [5]. Regardless of these uncertainties, evidence supports an 
upregulation of circulating activated leukocytes and pro-inflammatory cytokines, chiefly interleukin- 6 (IL-
6) and Tumour necrosis factor-α (TNF-α) in PE compared to normotensive pregnancy [4].  
The acute-phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP) increase 1000-fold 
reaching a maximum of approximately 500-1000µg/ml during inflammation, infection and trauma [3, 7]. 
Both SAA and CRP are secreted and synthesized by hepatocytes in response to the cytokines, interleukin-
6 (IL-6) and TNF-α [5, 8]. However, the role of these markers in PE is conflicting [3, 5, 9, 10]. Moreover, 
CRP levels is a potential and independent predictor of cardiovascular disease (CVD) and HIV disease 
progression [11-13]. 
South Africa (SA) is the epicenter of the HIV global pandemic with devastating consequences on women 
of reproductive age [14-16]. The prevalence of HIV in pregnancy is estimated at 37%, specifically in the 
province of KwaZulu-Natal whilst 83% of all maternal deaths due to hypertensive disorders is attributed to 
PE development [15, 16]. The opposing immune responses reflected in HIV-associated PE suggest 
neutralization of the immune hyper- reactivity exhibited by PE with a lowered predisposition to PE 
development in HIV positive individuals. However, the use of highly active antiretroviral therapy 
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(HAART), provides conflicting results [16-18]. Therefore, the aim of this study was to evaluate the role of 
SAA and CRP in HIV-associated PE.  
 
METHOD AND MATERIALS 
Study Population 
Permission to conduct this study was obtained from the Department of Health, the hospital manager and 
from the institutional Biomedical Research Ethics Committee (Reference Number: BE211/17). Women 
were purposively recruited at Prince Mshiyeni Memorial Hospital in KwaZulu-Natal, Durban, South Africa. 
All women gave informed consent for participation in the study. The study population was inclusive of 76 
pregnant women divided into two groups based on pregnancy type ie., normotensive (n=38) and pre-
eclamptic (n=38, new onset blood pressure of ≥ 140/90 mmHg and proteinuria of ≥ 300/24 hr). The study 
population was further stratified based on HIV status, ie., HIV-positive normotensive (n=19), HIV-negative 
normotensive (n=19), HIV-positive pre-eclamptic (n=19) and HIV-negative pre-eclamptic (n=19).  
 
Exclusion criteria: women with chronic diabetes, cardiac disease, chronic hypertension, gestational 
diabetes, chronic diabetes, pre-existing seizure disorders, chronic renal disease, sickle cell disease, 
abruption placentae, antiphospholipid antibody syndrome, chorioamnionitis, polycystic ovarian syndrome, 
eclampsia, thyroid disorder, unknown HIV status, no antenatal care as well as those who did not give 
informed consent were excluded. 
 
Inclusion criteria: diagnosis of pre-eclampsia based only on hypertension and proteinuria, known HIV 




The inclusion and exclusion criteria of the cases matched those of the controls except for a diagnosis of 




Maternal serum samples were stored at -80 ֯C until use. Samples aliquots were centrifuged at 1000 rpm for 
10 min at 25 ֯C and the supernatant used for the measurement of serum CRP and SAA. A multiplex 
immunoassay was performed using a ProcartaPlex Human Basic Kit (cat. number: EXP010-10420-901); 
ProcartaPlex Human SAA (cat. number: EPX01A-12136-901) and a human CRP Simplex Kit (cat. 
Number: EPX010-10420-901) as per the manufacturer’s instructions. Coupled magnetic beads were added 
into each well of the assay plate. Four-fold serial dilutions of both the standard and sample were then 
prepared and dispensed into designated wells followed by washing. Incubation allowed for the interaction 
of the antigen (SAA and CRP) with the capture antibody-coupled beads. Biotinylated detection antibodies 
were added with subsequent addition of streptavidin-phycoerythrin (SAPE) to complete the reaction. Plates 
were read on a Bio-Plex® MAGPIX™ Multiplex system (Bio-Rad Laboratories Inc., USA). Data from the 
multiplex analysis were obtained using the Bio-Plex Manager™ version 4.1 software. 
 
Statistical Analysis 
IBM SPSS Statistics (version 24) and Graphpad Prism (version 5, Software Inc., 2007) were utilised to 
analyse data. Descriptive statistics for continuous data were reported as median, interquartile range and 
mean ± standard deviation. Non-parametric Mann Whitney U and Kruskal-Wallis H tests were used to 






A summary of patient demographics of the overall study population are outlined in Table 1.  Gestational 
age, diastolic and systolic blood pressures were significantly different between the PE compared to the 
normotensive pregnancy groups (p < 0.0001 each). Additionally, maternal age (p = 0.15) and weight (p= 
0.21) were similar albeit both slightly higher in the PE group compared to the normotensive pregnant group.  
Parity was similar between the normotensive pregnant vs PE group [median- 1.00 (1.0-2.0); p = 0.66] albeit 
non-significantly. The mean Body Mass Index (BMI) was 29.64 ± 5.68 kg/m2 in the normotensive group 
and was slightly higher in the PE group (31.65 ± 6.43 kg/m2) albeit non-significantly (p = 0.11). The mean 
birth weight of the infants was significantly different between the normotensive pregnant (3.26 ± 0.36 kg) 
vs PE group (2.33 ± 0.96 kg) (Mann-Whitney U= 242.0, p< 0.0001). 
 
Serum concentrations of CRP and SAA 
Serum concentrations (pg/mL) of CRP and SAA are summarised in Table 2 and illustrated in Figures 1-5. 
CRP levels based on pregnancy type: Irrespective of HIV status, a significant difference in CRP expression 
were noted between the normotensive pregnant vs PE groups (Mann-Whitney U = 463.5; p = 0.0073). A 
reduction of CRP levels in PE (mean = 113 pg/mL; 95% CI: 31.3-194.7) vs the normotensive pregnant 
(mean = 238.3 pg/mL; 95% CI: 112.8-363.9) group was evident.  
 
CRP levels based on HIV status: In contrast, there was no statistical significance in CRP concentration 
between HIV-positive vs HIV-negative pregnant groups (p > 0.05), regardless of pregnancy type. 
Nonetheless, elevated CRP levels were observed in the HIV-positive (mean = 181.9 pg/mL; 95% CI: 66.48-
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297.4) compared to the HIV-negative group (mean = 140.4 pg/ml; 95% CI: 53.7-227.0) albeit non-
significantly (Mann-Whitney U = 690.0; p = 0.7434). 
 
CRP levels across all study groups: Decreased CRP levels were noted in the HIV-positive PE compared to 
the HIV-negative PE pregnant group, however these did not differ significantly (Mann-Whitney U = 164.0; 
p = 0.64). Additionally, CRP were significantly reduced in HIV-positive PE compared to the HIV-positive 
normotensive pregnant group (Kruskal-Wallis H = 10.45; p < 0.0151). 
 
SAA levels based on pregnancy type: There was no significant difference between PE vs normotensive 
pregnant women irrespective of HIV status (Mann-Whitney U = 546.5; p = 0.0690). 
 
SAA levels based on HIV status: The level of SAA was similar between HIV positive vs HIV negative 
groups (Mann-Whitney U = 648; p = 0.44) regardless of pregnancy type. 
SAA levels across all study groups: There was no significant difference in the serum concentration of SAA 
across study groups (Kruskal-Wallis H = 6.884; p = 0.76). Although serum SAA levels did not differ, an 
increasing trend was noted with regards to HIV status ie., in HIV- positive (mean = 73.5 pg/mL; 95% CI: 
52.6-94.4) vs HIV -negative (mean = 67.97 pg/mL; 95% CI: 59.8-76.2) and PE-positive (mean = 90.1 








In the duality of HIV associated PE, a discrepancy with regard to immune response and antiretroviral usage 
exists [16-18]. In this study, the pentraxin, CRP was significantly downregulated in PE compared to 
normotensive pregnancies.  However, SAA remained similar between groups. 
     
CRP is a major acute-phase protein and marker of overall systemic activity during inflammation [19, 20]. 
CRP together with other pro-inflammatory cytokines have been implicated as mediators of inflammation 
and endothelial dysfunction [12, 18]. Therefore, our results are unexpected as excessive inflammatory 
response and endothelial dysfunction are both characteristic features of PE [5].  Disturbances in the normal 
functioning of the endothelium results in altered coagulation, loss of vascular integrity thereby creating a 
pro-inflammatory environment [9, 21]. In contrast to normal pregnancy, where there is increased nitric 
oxide synthesis, nitric oxide synthetase expression is downregulated by CRP and TNF-α which results in 
decreased production of nitric oxide [9, 22]. The consequence is widespread endothelial dysfunction which 
is one of the clinical manifestations reflected in PE due to maternal endothelium injury [22]. Furthermore, 
since PE is an inflammatory disorder, CRP, IL-6 and TNF-α levels are expected to rise in PE compared to 
normal pregnancy.  
 
In contrast to our findings, Qui et al., [4], showed increased CRP levels that correlate with pre-pregnancy 
BMI.  Pre-pregnancy BMI could be an independent predictive tool for PE development in lean women; 
however, they failed to demonstrate this association in overweight women. In our study, a higher pregnancy 
BMI occurred in PE compared to the normotensive groups.  Baseline concentrations of CRP correlate with 
body mass index (BMI) and obesity is one of the risk factors of PE and cardiovascular diseases (CDVs) [3, 
4, 23]. Similarly, Engin-Ustun et al., [5], demonstrated increased levels of CRP in PE compared to 
normotensive pregnancy. Moreover, in a cross-sectional study of a high PE-risk population, CRP together 
with pro-inflammatory cytokines, IL-6 and TNF-α, were higher in women with PE compared with non-
pregnant controls and normotensive pregnant women [10]. Furthermore, Udenze et al., [24], reported 
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similar results in IL-6, TNF-α and CRP in patients with severe PE compared to healthy pregnant women. 
These studies however, were not confounded by HAART usage. Notably, the discrepancy of CRP may be 
due to immune reconstitution due to the dual antiretroviral therapy rollout in South Africa (nevirapine plus 
HAART administration).   
However, Kristensen et al., [9] found no significant difference in CRP between PE and normotensive 
pregnant women. It is plausible to suggest that the downregulation of CRP levels observed in this study 
may also be due to impaired functioning of hepatocytes which are enhanced by adipocytes and steroid 
hormones, hence the influence of BMI. 
 
Our study also demonstrates no significant difference in SAA expression between normotensive pregnant 
and pre-eclampsia, albeit with an elevated trend in PE. In contrast to our finding, SAA has been reported 
to be significantly elevated in PE compared to healthy pregnant women with a positive significant 
correlation with CRP level [5]. Since SAA strongly correlates with CRP expression, a known inflammatory 
marker, increased SAA would therefore contribute in the pathogenesis of PE. Nevertheless, similar to our 
findings, Kristensen et al., [9], reported no significant difference in SAA levels between PE versus both 
normotensive and non-pregnant controls. Data on SAA levels in PE is limited and conflicting results have 
been reported [3, 5]. Our findings of similar serum SAA levels between PE and healthy pregnant women 
are corroborated by Erdogan and colleagues [3]. However, they emphasize minor differences of SAA levels 
between the maternal blood and cord blood in both PE and normotensive pregnant women, suggesting a 
lack of SAA transfer via the placenta.  
 
SAA has a short half-life in serum, hence concentrations decline rapidly during recovery following a quick 
rise after an inflammatory stimulus [25]. Both HAART therapy and the short half-life of SAA may explain 
the non-significant increase noted in our study. Moreover, Gatt et al., [26] showed that SAA was involved 
in the modulation of neutrophil function. Furthermore, SAA has an inhibitory effect on leukocytes [27] 
verifying a modulatory role for SAA in inflammation.  
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South Africa remains the epicenter of the global HIV pandemic, specifically in women of reproductive age 
and a high prevalence of pre-eclampsia (12%) [15, 16]. An increasing body of research interest is still 
focused on the interaction of HIV infection and PE as there is no concordance on the relationship between 
these two diseases [18]. It is possible that the suppressed immune status in HIV infection is slightly 
neutralised during pregnancy with further intensification of the neutralisation by PE. However, data is 
controversial with regard to immune reconstitution following the use of highly active antiretroviral therapy 
(HAART) in normal pregnancy, and the predisposition to PE development [2, 17, 28]. 
 
 In our study, we demonstrate no significant difference in both CRP and SAA based on HIV status. A 
plausible explanation may be the immune restoration brought about by the antiretroviral therapy. 
Particularly, HAART regimens are associated with endothelial dysfunction and long term complications 
such as cardiovascular diseases and lipodystrophy [29]. In the study of Machado and colleagues [17], the 
authors observed that the use of HAART at conception was a risk factor for the development PE and 
eclampsia.  
 
A limitation of our study is the duration of antiretroviral (ARV) treatment ie., pre-pregnancy or intra-
pregnancy, which was incomplete for the study population.  Moreover, ARV treatment type was variable. 
Some women were on triple [HAART, zidovudine (AZT) and nevirapine] whilst others received dual ARV 
(AZT and nevirapine) therapy. Viral load was not assessed as it is not a standard of care practice in South 
Africa. The standard practice guidelines for HIV treatment during pregnancy in South Africa, recommends 
all HIV positive pregnant women to start ARV therapy immediately regardless of CD4 count.   
We were unable to correlate CRP and SAA expression with severity of HIV infection due to the lack of 
CD4 T cell count. However, the study of Lau et al., [30], noted that patients who progressed to Acquired 
Immunodeficiency Virus (AIDS) had higher CRP levels than those who remained AIDS free and increasing 
inflammation was associated with disease progression. Nevertheless, the decreased CRP levels in the HIV-
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positive PE group in our study are suggestive of some neutralization of the exaggerated immune response 
in PE by HIV infection.  
 
CONCLUSION 
Finally, this study demonstrates significant reduction of CRP with a concomitant non-significant increase 
of SAA in PE compared to normotensive pregnant women. We suggest immune neutralization in HIV 
associated PE with immune reconstitution in HAART treated individuals. However, further studies with a 
larger sample size are required to evaluate these biomarkers as potential predictive tools of PE and their 
prognostic role in HIV associated PE.  
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Table 1: Demographic and clinical characteristics of the study population 
 N- N+ PE- PE+ 
Number 19 19 19 19 
Maternal age (years) 24 ± 5.26 27.42 ± 6.52  27.05 ± 6.63 27.62 ± 4.11 
Gestational age (weeks) 38.50 ± 1.34       38.69 ± 1.30 35.22 ± 4.55 35.00 ± 4.34 
Maternal Weight (kg) 77.10 ±15.97      68.11 ± 7.97 75.47 ± 13.27 77.45 ± 16.78 
Systolic BP (mmHg) 119.53 ±8.77     118.58±10.66     170.95±18.16 166.62 ± 22.11 
Diastolic (mmHg) 69.32 ±11.88 74.68 ± 10.24     104.05±14.25 103.69 ± 15.41 
Values are presented as mean ± standard deviation; n= 76; BP: Blood Pressure; N-: Normotensive HIV 
negative; N+: Normotensive HIV positive; PE-: Pre-eclamptic HIV negative; PE+: Pre-eclamptic HIV positive;  
 
The mean systolic and diastolic blood pressure was higher in the pre-eclamptic (169.0mmHg ±19.32 and 
104.3mmHg ±14.29) compared with the normotensive (119.1mmHg ±9.64 and 72.0mmHg ±11.28) 
pregnant group respectively. Furthermore, the mean gestation age was higher in the normotensive versus 















 HIV - (n= 19) HIV +(n= 19) HIV - (n= 19) HIV + (n= 19) 
CRP 
(pg/mL)  
53.4(18.09-228.4) 68.8(30.76-379.1) 21.02(13.76-60.25) 17.36(8.85-68.80) 
SAA 
(pg/mL) 
71.64(39.22-86.08) 41.48(30.89-84.20) 74.21(50.31-91.15) 86.04(52.13-86.04) 
Values are represented as median and interquartile range.  Key: HIV - : HIV negative; HIV +: HIV 





















































Figure 1: Serum levels of C-reactive protein (pg/mL), in normotensive and pre-eclamptic pregnancy,  
irrespective of HIV status. Results are presented as median and interquartile range.**Serum concentrations  























Figure 2: Serum concentrations of circulating maternal serum amyloid A (pg/mL) between normotensive 
and pre-eclamptic pregnancy groups irrespective of HIV status. Results are presented as median and 
interquartile range. No significant difference in serum concentrations was observed between the two groups, 













































































Figure 3: Serum concentrations of circulating maternal C-reactive protein (pg/mL) between HIV negative 
and HIV positive groups irrespective of pregnancy type. Results are presented as media and interquartile 










































Figure 4: Serum concentrations serum amyloid A (pg/mL) between HIV negative and HIV positive 
groups irrespective of pregnancy type. Results are presented as median and interquartile range. Serum 




































































Figure 5. Serum concentrations (median and interquartile range) of (A) C-reactive protein (pg/mL) and 
(B) serum amyloid A (pg/mL) in HIV-negative normotensive (N-), HIV-positive normotensive (N+), 
HIV-negative pre-eclamptic (PE-) and HIV-positive pre-eclamptic (PE+) groups. *Serum concentrations 
of CRP between N+ and PE+ groups were significantly different, p = 0.0151. Serum concentrations of C-



























Pre-eclampsia, an obstetric disorder specific to human pregnancy remains a major cause of maternal 
mortality and morbidity globally (Chaiworapongsa et al., 2014a, Levine  et al., 2004). In South Africa, the 
high maternal mortality rates are attributable to HIV infection, haemorrhage and hypertensive disorders 
with 83% of the latter deaths emanating from pre-eclampsia development (Moodley, 2011, Mothers, 2014). 
Furthermore, in the province of KwaZulu-Natal the prevalence of PE is 12% (Mothers, 2014) whilst HIV 
in pregnancy is estimated at 37.7% (Thakoordeen et al., 2017). While there is no cure for this disorder, the 
only resolution is delivery of the placenta and fetus (Chaiworapongsa et al., 2014b, Moodley, 2011).  
One of the clinical manifestations reflected in PE is widespread endothelial dysfunction, postulated to be 
enhanced by an increased proinflammatory environment normally provoked by inflammation (Mustafa, 
2012, Udenze, 2015). Although a dose-response relationship between PE and inflammation is yet to be 
established, it has been proposed that the latter may intensify the effects of the imbalance in circulating 
angiogenic factors reflected in PE. Thus inflammation alone, is not sufficient to cause the disorder (Ramma 
and Ahmed, 2011). 
Marked increase of acute phase proteins and other known markers of inflammation have been reported in 
pre-eclamptic versus normotensive pregnant women (Maharaj, 2017, Hubel, 2008). However, conflicting 
results have been reported with regard to CRP and SAA levels in PE (Qiu et al., 2004, Erdoğan et al., 2012). 
Notably, an increase, decrease and similarities in their circulating concentration  have been demonstrated 
in both PE and normotensive pregnancy (Teran, 2001, Kristensen, 2009, Erdoğan et al., 2012).  
Both CRP and SAA levels increase in response to inflammation, acute and chronic infections. In contrast 
however, viral infections are thought to correlate with lower CRP expression compared with those elicited 
by bacterial infections (Saljoughian, 2008, Lau et al., 2006). CRP is known to bind with high affinity to 
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phosphocholine on microbes thereby inducing phagocytosis, destruction and clearance of the microbe 
(Samikkannu et al., 2013, Chandrashekara, 2014).  
SAA production has been shown to induce  the proinflammatory cytokines,  IL-6, IL-1 and TNF-α 
(Samikkannu et al., 2013, Engin-Üstün et al., 2007). Elevated SAA occur in many inflammatory disorders 
such as atherosclerosis and thrombosis implicating it’s potential role in endothelial dysfunction and in the 
development of cardiovascular disease (Sun, 2015, Hua et al., 2009). Although the main physiological role 
of SAA is poorly understood, various functions have been demonstrated which includes inducing adhesion 
and migration of monocytes and neutrophils, chemoattractant and cytokine-like functions, involvement in 
the cholesterol transport system and tissue infiltration of polymorphonuclear leukocytes (Urieli-Shoval, 
2000, Thorn et al., 2004, Sun, 2015).  
Whilst the data on SAA in the pathogenesis of PE is limited, the relationship of acute phase proteins in 
HIV-associated pre-eclampsia remains obscure and is investigated in the duality of HIV infection and PE 
(HIV-associated PE).  
Pre-eclampsia is initiated by poor placentation, (Mustafa, 2012). In PE, defective trophoblast invasion 
results in failure of spiral artery remodelling with subsequent reduced organ perfusion and placental 
ischaemia (Chaiworapongsa et al., 2014a, Gathiram and Moodley, 2016). The resultant release of various 
maternal circulating factors creates an increased proinflammatory environment (TNF-α, IL-6 and 8) which 
can mediate and contribute to the widespread endothelial dysfunction exhibited by PE (Udenze, 2015, 
Maharaj, 2017). High cytokine levels are known to elevate blood pressure with a concomitant decline in 
renal function, in studies using pregnant animal models (Udenze, 2015). Also, the synthesis of CRP and 
SAA by liver hepatocytes is induced by increased levels of cytokines, mainly TNF-α and IL-6 (Udenze, 
2015). Thus, the inflammatory relationship between acute-phase proteins and cytokines as depicted by 
increased concentrations, is expected in PE compared to normotensive pregnant women. 
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Nonetheless, this study demonstrates a significant downregulation of CRP with concomitant elevation of 
SAA in PE compared to normotensive pregnancy albeit non-significant. Although our results are 
unexpected, they are corroborated by the findings of Kristensen et al.,(2009) and colleagues who found no 
increase in both CRP and SAA levels in PE compared to healthy pregnant women (Kristensen, 2009).  It 
must be noted that in our study all HIV infected women received anti-retroviral therapy which is a standard 
of care in South Africa. Nonetheless, in two previous studies the levels of proinflammatory cytokines TNF-
α, TNF-γ and IL-6 at the 18th week of gestation were not increased in women who developed PE compared 
to normotensive pregnant women (Ramma and Ahmed, 2011).  In our study, despite SAA expression been 
similar between PE and normotensive pregnant women, an elevated trend of SAA expression was noted in 
PE versus healthy pregnant women. These findings are consistent with those reported by Erdogan et al., 
(2012).  
SAA is also a high-density lipoprotein and precursor of Amyloid A fibrils in systemic Amyloid A 
amyloidosis, an autoimmune disease with characteristics of chronic inflammation (Targonska-Stepniak and 
Majdan, 2014). The functions of SAA are varied and recent studies have shown that this protein may be 
more regulatory than proinflammatory as it also displays anti-inflammatory functions (Sun, 2015). 
Moreover, SAA declines rapidly during recovery due to its short-half life in serum (Hillström et al., 2010).  
The use of HAART in our study in combination with the short half-life of SAA may have resulted in the 
similar SAA levels observed between the groups. 
In contrast to our findings, Engin-Ustun et al., (2007) reported elevated CRP and SAA levels in PE pregnant 
women and this interrelation was suggestive of a potential role in the pathogenesis of PE (Engin-Üstün et 
al., 2007). Moreover, in the study of Teran et al., (2001), increased CRP and proinflammatory cytokine 
levels were observed in pre-eclamptic versus normotensive pregnant controls.  
Increasing levels of proinflammatory cytokines impair endothelial function and inhibit expression of nitric 
oxide synthetase which results in decreased nitric oxide production with subsequent endothelial 
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dysfunction, a hallmark of PE (Teran, 2001). Moreover, in animal studies the downregulation of nitric oxide 
synthetase can produce similar characteristics as those displayed in PE (Mustafa, 2012). 
Our results were confounded by the use of HAART, a fact not considered in the above studies. HAART-
induced HIV suppression restores immune activity to some extent by increasing CD4+ T cell count 
therefore, this alters the level of inflammatory markers and delays HIV disease progression (Maharaj et al., 
2017) 
Despite our demonstrating no significant difference in both CRP and SAA based of HIV status, an upward 
trend was observed in HIV positive compared to HIV negative women. Pre-eclampsia and HIV/AIDS 
infection are inflammatory conditions known to play significant roles in immune activation and 
dysfunction. The interaction of these two conditions however, is still contentious as data on the use of 
HAART in HIV-associated PE is conflicting (Maharaj et al., 2017, Machado et al., 2014, Suy et al., 2006). 
In the study of Suy and colleagues (2006), the authors found an increased risk of PE development in HIV 
infected women who were exposed to HAART treatment prior to pregnancy (Suy et al., 2006). Moreover, 
Sansone et al., (2016) demonstrated that HIV infected pregnant women exhibited a similar risk of PE 
development than uninfected women possibly due to the use of HAART (Sansone et al., 2016). However, 
Boyajian et al., (2012) reported no difference in the risk of PE development between HAART treated HIV 
positive and HAART-naive pregnant women (Boyajian et al., 2012). 
Based on HIV status our findings of elevated CRP and SAA (non-significant) are in part corroborated by 
those of Samikkannu et al., (2013). In their study, alcohol and illicit drug abusers infected with HIV had 
increased CRP and SAA concentrations implicating a role in viral replication and disease progression. 
However, the authors concluded that elevated concentrations of these proteins appear to be accelerated by 
alcohol and drugs of abuse (Samikkannu et al., 2013). Nevertheless, Lau et al., (2006) associated increasing 
inflammation with disease progression and found that higher CRP levels were present in patients who later 
progressed later to AIDS compared to those who remained free of AIDS. A plausible explanation of the 
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similarities in CRP and SAA levels based on HIV status (HIV positive vs HIV negative) may be due to the 
immune reconstitution by HAART. 
Additionally, across all study groups we demonstrate a significant decrease of CRP in HIV positive PE 
versus HIV positive normotensive pregnant women. Decreased CRP levels in the HIV-positive PE group 
are suggestive of some neutralization of the exaggerated immune response in PE by HIV infection.  
 
CONCLUSION 
In conclusion, this study demonstrates significant reduction of CRP with a concomitant non-significant 
increase of SAA in PE compared to normotensive pregnant women. Our results in part suggest immune 
neutralization in HIV associated PE in HAART treated individuals. However, further studies with a larger 
sample size are required to evaluate these biomarkers as potential predictive tools of PE and their prognostic 
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